China Universal Asset Management Co. Ltd. Takes Position in NewAmsterdam Pharma (NASDAQ:NAMS)

China Universal Asset Management Co. Ltd. bought a new stake in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 19,589 shares of the company's stock, valued at approximately $503,000.

Several other large investors also recently bought and sold shares of the business. Frazier Life Sciences Management L.P. lifted its stake in shares of NewAmsterdam Pharma by 5.1% in the 3rd quarter. Frazier Life Sciences Management L.P. now owns 12,855,194 shares of the company's stock valued at $213,396,000 after purchasing an additional 628,251 shares during the last quarter. Janus Henderson Group PLC raised its holdings in NewAmsterdam Pharma by 51.1% during the 3rd quarter. Janus Henderson Group PLC now owns 1,540,729 shares of the company's stock valued at $25,607,000 after buying an additional 520,772 shares during the period. Jennison Associates LLC lifted its position in NewAmsterdam Pharma by 8.9% in the third quarter. Jennison Associates LLC now owns 1,020,278 shares of the company's stock worth $16,937,000 after buying an additional 83,115 shares during the last quarter. ArrowMark Colorado Holdings LLC boosted its stake in NewAmsterdam Pharma by 19.5% during the third quarter. ArrowMark Colorado Holdings LLC now owns 354,975 shares of the company's stock worth $5,893,000 after buying an additional 57,806 shares during the period. Finally, FMR LLC increased its position in NewAmsterdam Pharma by 35.6% during the third quarter. FMR LLC now owns 330,412 shares of the company's stock valued at $5,485,000 after acquiring an additional 86,712 shares during the last quarter. Institutional investors own 89.89% of the company's stock.

Insider Transactions at NewAmsterdam Pharma

In related news, major shareholder Nap B.V. Forgrowth sold 8,530 shares of the company's stock in a transaction dated Friday, November 15th. The shares were sold at an average price of $25.02, for a total value of $213,420.60. Following the completion of the sale, the insider now directly owns 11,812,033 shares of the company's stock, valued at $295,537,065.66. This represents a 0.07 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last three months, insiders have sold 446,730 shares of company stock valued at $11,438,695. 19.50% of the stock is currently owned by company insiders.

NewAmsterdam Pharma Trading Up 0.2 %

NAMS traded up $0.05 on Thursday, reaching $21.10. 756,538 shares of the company traded hands, compared to its average volume of 678,635. NewAmsterdam Pharma has a one year low of $15.19 and a one year high of $27.29. The firm has a fifty day simple moving average of $23.58 and a two-hundred day simple moving average of $20.05.

Wall Street Analyst Weigh In

NAMS has been the subject of several analyst reports. Scotiabank raised their target price on shares of NewAmsterdam Pharma from $35.00 to $47.00 and gave the stock a "sector outperform" rating in a report on Wednesday, December 11th. HC Wainwright reissued a "buy" rating and issued a $48.00 price objective on shares of NewAmsterdam Pharma in a research note on Tuesday, January 14th. Royal Bank of Canada restated an "outperform" rating and set a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Friday, January 24th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $36.00 price target on shares of NewAmsterdam Pharma in a report on Thursday, December 5th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average price target of $41.60.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.